Amelioration of Renal Ischemia–Reperfusion Injury by Inhibition of IL-6 Production in the Poloxamer 407–Induced Mouse Model of Hyperlipidemia
Authors:
- 1 January 2009
- journal article
- research article
- Published by Japanese Pharmacological Society in Journal of Pharmacological Sciences
- Vol. 110 (1) , 47-54
Abstract
It is largely unknown whether hyperlipidemia is involved in the pathobiology of renal ischemia–reperfusion (I/R) injury that is an important cause of acute kidney injury. Here we studied the effect of experimental dyslipidemia on renal I/R injury. Renal I/R injury was less severe in hyperlipidemic mice treated with poloxamer 407 than in the control mice. Cytokine analyses revealed decreased levels of renal and serum IL-6 in the hyperlipidemic mice after renal I/R. Protection from renal I/R injury in the hyperlipidemic mice was diminished by administration of recombinant IL-6. Concanavalin A–induced IL-6 release from cultured splenocytes derived from the hyperlipidemic mice was lower than that from splenocytes of normal mice. In hypercholesterolemic apolipoprotein E–knockout mice, in which renal I/R injury is less severe than in control mice, renal I/R–induced IL-6 production was also less than that in controls. In angiopoietin-like 3–deficient mice, which were hypolipidemic, renal dysfunction and renal IL-6 level after I/R were similar to those of control mice. Our data indicate that the presence of experimental hyperlipidemia may be associated with a decreased risk of renal I/R injury, possibly mediated by reduced renal IL-6 production after the insult and extend the notion that an anti-IL6 agent would be useful for the treatment of acute kidney injury.Keywords
This publication has 32 references indexed in Scilit:
- Pravastatin improves renal ischemia–reperfusion injury by inhibiting the mevalonate pathwayKidney International, 2008
- The Effect of Lipoproteins on the Development and Progression of Renal DiseaseAmerican Journal of Nephrology, 2008
- Oncogenic Ras-induced secretion of IL6 is required for tumorigenesisGenes & Development, 2007
- Lipoprotein Metabolism and Lipid Management in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2007
- Anti-Inflammatory Activity in Vitro and in Vivo of the Protein Farnesyltransferase Inhibitor TipifarnibThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Ischemic acute tubular necrosis models and drug discovery: a focus on cellular inflammationDrug Discovery Today, 2006
- Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E‐related disorders in humansThe FASEB Journal, 2001
- Protective effect of l-arginine on hypercholesterolemia-enhanced renal ischemic injuryAtherosclerosis, 1999
- Altered lipid metabolism in apolipoprotein E-deficient mice does not affect cholesterol balance across the liverHepatology, 1996
- Regulation of the mevalonate pathwayNature, 1990